Fujifilm isn’t slowing down on its expansion roll. Just a few months after it bought Shenandoah Biotechnology for an undisclosed sum, the Japanese conglomerate has unveiled a $1.6 billion investment to expand the cell culture manufacturing services of Fujifilm Diosynth Biotechnologies, a CDMO subsidiary.
The investment will benefit its sites in Hillerød, Denmark, and Texas, and create approximately 450 jobs.
In Denmark, Fujifilm Diosynth will expand its capacity to support large-scale batch production through the addition of eight 20,000-liter bioreactors and two downstream processing streams, making it largest end-to-end CDMO in Europe. Once the expansion is complete, the site will feature twenty 20,000-liter bioreactions for drug substance production, plus drug product and finished good services.
The Denmark facility’s sustainable features, such as an electric boiler rather than one powered by natural gas, will support Fujifilm’s new Green Value Climate Strategy and remove its dependency on fossil fuels. Fujifilm Diosynth is also investing in programs that aim to reduce water consumption.